Cosmos’ Cana completes facility upgrades, secures manufacturing agreement

Cosmos Health’s Cana Laboratories has completed the latest upgrades to its manufacturing capabilities and capacities and secured a contract manufacturing agreement with Provident Pharmaceuticals. Cosmos Health completed its acquisition of Cana in July 2023 and has since invested in upgrading Cana’s Athens facility, which is licensed under European Good Manufacturing Practices and certified by the European Medicines Agency laying the foundation for future growth. As a result, Cana is now ramping up revenue generation from manufacturing its own products as well as those of third parties. Cana’s facilities can accommodate a wide range of pharmaceuticals, including tablets, capsules, syrups, nasal sprays, creams, gels, and ointments. In line with this strategy, the Company has entered into a contract manufacturing agreement with Provident to support their growth aspirations. Specifically, the contract relates to the manufacturing of 4.32 million units of DE3-SOLE OR.SOL.SDC 25000 IU/2.5ML.